Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl for breakthrough dyspnea in cancer patients
NCT01515566Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2012
- Primary completion
- Apr 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fentanyl in Dyspnea, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Retention Rate at 100 months. Started Apr 2012; status: completed.
02
Drugs
fentanyl
03
Conditions
Dyspnea
Beyond the preview
Go deeper on NCT01515566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515566.